MAP2K7 and melanoma: The MAPK pathway is an important therapeutic target in melanoma: BRAF, MEK, and combined BRAF/MEK inhibition with small molecule kinase inhibitors are successful treatment strategies in patients with BRAF mutant metastatic melanoma (6–10).